Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. (Q47905437)

http://europepmc.org/abstract/MED/28841827

6 February 2018

title

Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

main subject

diabetic macular edema

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

author name string

Yule Xu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

Wei Xu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

Yunli Niu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

Zhen Wang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

publication date

25 August 2017

1 reference

http://europepmc.org/abstract/MED/28841827

6 February 2018

published in

BMC Ophthalmology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

page(s)

158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/s12886-017-0554-8

13 May 2020

exact match

0 references

cites work

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Corticosteroid use for diabetic macular edema: old fad or new trend?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Intravitreal aflibercept for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

The discovery of placenta growth factor and its biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12886-017-0554-8

VEGF-initiated blood-retinal barrier breakdown in early diabetes.

21 January 2018

1 reference

12 December 2020

Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys

1 reference

12 December 2020

Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration

1 reference

12 December 2020

Profile of conbercept in the treatment of neovascular age-related macular degeneration

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

12 December 2020

Ten-year incidence of visual loss in a diabetic population

1 reference

12 December 2020

10.1186/S12886-017-0554-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

Dimensions Publication ID

13 May 2020

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12886-017-0554-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6389086&resulttype=core&format=json

13 May 2020

1 reference